创新药板块全线回调，创新药ETF富国、港股通创新药ETF和创新药ETF国泰分别跌5.14%、4.25%和3.3%

Core Viewpoint - The recent policy measures from the National Healthcare Security Administration and the National Health Commission are seen as long-term benefits for the innovative drug sector, although there may be short-term profit-taking effects following the initial market reactions to the policy [3][4]. Group 1: Policy Measures - The policy includes 16 measures across five areas to support the development of innovative drugs, such as enhancing R&D support and integrating innovative drugs into insurance coverage [3]. - Key points include using healthcare data to improve R&D efficiency, establishing a commercial insurance directory for innovative drugs, and exploring temporary inclusion of essential innovative drugs in insurance coverage during public health emergencies [3]. Group 2: Market Performance - The Hong Kong innovative drug index saw a significant increase of 54.78% in the first half of the year, leading to concerns about the sustainability of this growth [4]. - Following the policy announcement, many innovative drug stocks experienced gains exceeding 10%, but subsequent profit-taking led to a market correction [3][4]. Group 3: ETF Overview - There are 20 ETFs tracking indices related to innovative drugs, with the largest being the GF Fund's Hong Kong Innovative Drug ETF, which has a scale of 138.51 billion [5][7]. - The management fees for the innovative drug ETFs vary, with the lowest being 0.15% for certain funds [5][7]. Group 4: Future Outlook - The innovative drug industry is expected to transition from capital-driven growth to profit-driven growth by 2025, presenting opportunities for both performance and valuation recovery [5][8].